1. Home
  2. UXIN vs MPLT Comparison

UXIN vs MPLT Comparison

Compare UXIN & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Uxin Limited ADS

UXIN

Uxin Limited ADS

HOLD

Current Price

$3.00

Market Cap

723.7M

ML Signal

HOLD

MPLT

MapLight Therapeutics Inc.

N/A

Current Price

$27.30

Market Cap

811.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UXIN
MPLT
Founded
2011
2018
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
723.7M
811.3M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
UXIN
MPLT
Price
$3.00
$27.30
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$32.67
AVG Volume (30 Days)
182.8K
253.8K
Earning Date
04-10-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$245.77
N/A
Revenue Next Year
$44.72
N/A
P/E Ratio
$4.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.45
$12.24
52 Week High
$5.40
$30.28

Technical Indicators

Market Signals
Indicator
UXIN
MPLT
Relative Strength Index (RSI) 39.88 69.31
Support Level $2.49 $16.19
Resistance Level $3.13 N/A
Average True Range (ATR) 0.22 2.19
MACD -0.01 0.75
Stochastic Oscillator 25.81 74.24

Price Performance

Historical Comparison
UXIN
MPLT

About UXIN Uxin Limited ADS

Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates used car e-commerce platforms through its mobile applications and websites. It facilitates used car transaction services and financing solutions offered by third-party financing partners to buyers for their used car purchases. The company generates revenue through sales of the commission of salvage car sales, and interest income from the financial lease. The Group generates its revenues in China, and assets of the company are also located in China Area.

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.

Share on Social Networks: